A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06124807 on ClinicalTrials.gov · last registry update 2026-04-21

Finished 22 January 2025, after enrolling 179 people. Primary outcome, as filed: Percent Change From Baseline in Body Weight at Week 32. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.

Status: COMPLETED
Phase: P2
Drug: mazdutide
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 179
Started: 2023-11-17
Primary completion: 2025-01-22 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight at Week 32

Conditions studied

Obesity · Overweight and Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.